Is Anebulo Pharmaceuticals, Inc. (ANEB) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 79.2% / 30% | 0.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 79.2% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 95.7% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 79.2% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 95.7% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -69.7% | |
| Return on Assets (ROA) | -45.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$6M |
| Free Cash Flow | -$6M |
| Current Ratio | 6.2 |
| Total Assets | $12M |
Price & Trading
| Last Close | $0.99 |
| 50-Day MA | $0.72 |
| 200-Day MA | $1.81 |
| Avg Volume | 90K |
| Beta | -0.7 |
|
52-Week Range
$0.30
| |
About Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Anebulo Pharmaceuticals, Inc. (ANEB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Anebulo Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Anebulo Pharmaceuticals, Inc.'s debt ratio?
Anebulo Pharmaceuticals, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Anebulo Pharmaceuticals, Inc.'s key financial metrics?
Anebulo Pharmaceuticals, Inc. has a market capitalization of $36M. Return on equity stands at -69.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.